Sanofi Canada Media Room

Welcome to the Sanofi Media Room

Our Media Room is designed to provide reporters with company and product news, as well as key facts, figures and background information. To help you keep up with the latest news, we offer email alerts and RSS feeds. If you are a reporter and have questions about the company or our products, visit the Media Contacts page.

Press Releases

May 21, 2024

The National Advisory Committee on Immunization recommends BEYFORTUS® to protect all infants against RSV

The National Advisory Committee on Immunization (NACI) strongly recommends working towards a universal Respiratory Syncytial Virus (RSV) immunization program using BEYFORTUS® (nirsevimab).i BEYFORTUS

Apr 18, 2024

Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)

BEYFORTUS® (nirsevimab) is the first long-acting antibody approved in Canada for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants...

Apr 16, 2024

Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by 50%

Today, Sanofi, a global healthcare company announced an investment of $180M (CAD) at its Toronto Campus to build and update infrastructure to minimize its environmental footprint. This investment...